A5369: HIV-1-Gag Conserved-Element DNA Vaccine (p24CE) as Therapeutic Vaccination in HIV-Infected Persons with Viral Suppression on Antiretroviral Therapy

A5369: HIV-1-Gag Conserved-Element DNA Vaccine (p24CE) as Therapeutic Vaccination in HIV-Infected Persons with Viral Suppression on Antiretroviral Therapy
Recruiting
99 years or below
All
Phase 1
5 participants needed

Brief description of study

A5369 is a phase I/IIa, randomized, double-blind, placebo-controlled study to evaluate the safety, immunogenicity, and efficacy of p24CE/full-length Gag DNA, as a therapeutic vaccine in HIV-1 infected persons. The study targets to enroll 40 participants. All participants are well-suppressed on ART, current CD4 T cell counts greater than 500 cells/mm3, and nadir CD4 T cell counts greater than 350 cells/mm3. Each participant will receive active vaccine/placebo at weeks 0, 4, 12, and 24 delivered by electroporation after intramuscular injection. The primary efficacy outcome will be based on HIV-specific immunologic assays at baseline and week 26.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: ['HIV Infections']
  • Age: 99 years or below
  • Gender: All
Updated on 19 Feb 2024. Study ID: 830198

Find a site

Message sent successfully.
We have submitted the information you provided to the research team at the location you chose. For your records, we have sent a copy of the message to your email address.
If you would like to be informed of other studies that may be of interest to you, you may sign up for Patient Notification Service.
Sign up

Send a message

Enter your contact details to connect with study team

Email

View email

Phone

Phone country flag

View phone
Investigator Avatar

Primary Contact

First name*
Last name*
Email*
Phone number*
Preferred way of contact
Race
Ethnicity
Other language

Message For Non Enrolling By Invitation Trial

Select a study center that’s convenient for you, and get in touch with the study team.